
BioCorteX builds an emulator that predicts how a patient’s bacteria and immune system influence drug effectiveness. Their Carbon Mirror platform combines the Carbon Knowledge biology knowledge graph with AI models and biology data to simulate drug–bacteria interactions in the tumor microenvironment. Offered as a SaaS to pharmaceutical companies and researchers, the platform supports in silico trials, clinical trial design optimization, and therapeutic stratification. By surfacing microbiome-driven variability, BioCorteX aims to de-risk clinical programs and enable more targeted drug development at scale.

BioCorteX builds an emulator that predicts how a patient’s bacteria and immune system influence drug effectiveness. Their Carbon Mirror platform combines the Carbon Knowledge biology knowledge graph with AI models and biology data to simulate drug–bacteria interactions in the tumor microenvironment. Offered as a SaaS to pharmaceutical companies and researchers, the platform supports in silico trials, clinical trial design optimization, and therapeutic stratification. By surfacing microbiome-driven variability, BioCorteX aims to de-risk clinical programs and enable more targeted drug development at scale.
What they do: Emulator platform (Carbon Mirror) and microbiome knowledge graph (Carbon Knowledge) that model drug–microbiome–host interactions for in‑silico trials and trial optimization
Customers / use cases: Pharmaceutical companies and researchers for in‑silico trials, clinical trial design optimization, and therapeutic stratification
Founded: 2021
HQ / offices: London (registered) with offices in New York and Adelaide
Funding: $5.0M seed announced Mar 28, 2023
Predicting and modeling microbiome effects on therapeutic efficacy and optimizing clinical development to reduce trial risk.
2021
Biotechnology
$5,000,000
“Sofinnova Partners; Hoxton Ventures; Ride Home Fund”